0001193125-22-032205.txt : 20220209 0001193125-22-032205.hdr.sgml : 20220209 20220209114131 ACCESSION NUMBER: 0001193125-22-032205 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220209 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220209 DATE AS OF CHANGE: 20220209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471851754 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 22605186 BUSINESS ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 8-K 1 d276078d8k.htm 8-K 8-K
false 0001590877 0001590877 2022-02-09 2022-02-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 9, 2022

 

 

REGENXBIO Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-37553   47-1851754

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

9804 Medical Center Drive

Rockville, Maryland

   20850
(Address of principal executive offices)   (Zip Code)

(240) 552-8181

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   RGNX   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 7.01.

Regulation FD Disclosure.

On February 9, 2022, Roberto Giugliani, M.D., Ph.D., a principal investigator for REGENXBIO Inc.’s (the “Company”) Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (the “RGX-121 Trial”), presented an interim analysis of data from the RGX-121 Trial at the 18th Annual WORLDSymposium. Additionally, on February 9, 2022, Raymond Wang, M.D., a principal investigator for the Company’s Phase I/II trial of RGX-111 for the treatment of Mucopolysaccharidosis Type I (the “RGX-111 Trial”), presented an interim analysis of data from the RGX-111 Trial and a single-patient Investigational New Drug (“IND”) application for RGX-111 at WORLDSymposium. A copy of each of Dr. Giugliani’s and Dr. Wang’s presentation materials is available on the “Presentations and Publications” section of the Company’s website at www.regenxbio.com.

The information in Item 7.01 of this Current Report on Form 8-K and the presentation materials on the Company’s website shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01.

Other Events.

On February 9, 2022, the Company issued a press release announcing an interim analysis of data from the RGX-121 Trial (the “RGX-121 Press Release”) and a press release announcing an interim analysis of data from the RGX-111 Trial and the single-patient IND application for RGX-111 (the “RGX-111 Press Release”). Copies of the RGX-121 Press Release and the RGX-111 Press Release are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

 

Item 9.01.

Financial Statements and Exhibits.

(d)        Exhibits

 

Exhibit
No.

   

Description

99.1    RGX-121 Press Release dated February 9, 2022.
99.2    RGX-111 Press Release dated February 9, 2022.
104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    REGENXBIO INC.
Date: February 9, 2022     By:  

/s/ Patrick J. Christmas II

      Patrick J. Christmas II
      Executive Vice President and Chief Legal Officer
 EX-99.1 2 d276078dex991.htm EX-99.1 EX-99.1

EXHIBIT 99.1

 

LOGO

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposiumTM 2022

 

  •  

RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels

 

  •  

Dose-dependent reductions in CSF biomarkers observed; Cohort 3 patients approach normal levels of D2S6 biomarker

 

  •  

Measures of neurodevelopmental function from patients in Cohorts 1 and 2 demonstrate continued developmental skill acquisition up to two years after RGX-121 administration

 

  •  

Evidence of systemic enzyme expression and biomarker activity continues to be observed

 

  •  

Cohort 3 expansion using commercial-scale cGMP material is planned to start in 1H 2022

ROCKVILLE, Md., February 9, 2022 (PRNewswire) — REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from Cohorts 1-3 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome, are being presented at the 18th Annual WORLDSymposium™.

“We are pleased to share additional data from patients in Cohorts 1-3 of our RGX-121 Phase I/II trial,” said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO. “The interim data demonstrate dose-dependent reductions in CSF biomarkers across cohorts, and we are encouraged by the neurodevelopmental trajectories in patients from Cohorts 1 and 2, now up to two years after administration of RGX-121. We look forward to providing additional updates in this trial.”

“MPS II patients are in need of new treatment options that could address the neurological manifestations of the disease and help address the neurodevelopmental decline observed with currently available therapies” said Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil. “The data presented today continues to support the early positive signals seen in the emerging clinical profile of RGX-121 for the treatment of MPS II. I am encouraged by the biomarker activity and impact on neurodevelopmental improvements observed in this trial, and I look forward to additional updates.”

RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector. The primary endpoint of the trial is to evaluate the safety of RGX-121. Secondary and exploratory endpoints include biomarkers of α iduronate-2-sulfatase (I2S) enzyme activity in the CSF, serum and urine, neurodevelopmental assessments, and caregiver reported outcomes. RGX-121 is administered directly to the central nervous system (CNS). Patients were treated across three dose levels, 1.3x1010 genome copies per gram (GC/g) of brain mass (n=3), 6.5x1010 GC/g of brain mass (n=7), and 2.9x1011 GC/g of brain mass (n=3). REGENXBIO has expanded Cohort 3 to include patients who will be dosed using commercial-scale cGMP material, and plans to begin dosing these patients in the first half of 2022.

Data Summary and Safety Update

As of December 20, 2021, RGX-121 is reported to be well-tolerated across all cohorts with no drug-related serious adverse events (SAEs) in 13 patients dosed with RGX-121. Time of post-administration follow-up ranges from eight weeks to two years. Eight patients have completed the 48-week immunosuppression regimen per study protocol. Eight patients were receiving weekly, intravenous enzyme replacement therapy (ERT) at the time of enrollment, per standard of care; three of these patients have discontinued ERT, per investigator discretion, as allowed in the protocol.    

CSF Biomarker Data

Biomarker data from patients in all three cohorts indicate encouraging signals of I2S enzyme activity in the CNS following one-time administration of RGX-121. Heparan sulfate (HS) and D2S6, a component of HS closely correlated with severe MPS II, are glycosaminoglycans (GAGs) that are key biomarkers of I2S enzyme activity and are being measured in the cerebrospinal fluid (CSF) at baseline and after administration of RGX-121. The majority of patients in all three cohorts demonstrated reductions of HS in the CSF following RGX-121 administration at the last time point available with dose-dependent reductions seen at Weeks 8 and 24 post RGX-121 administration. At 8 weeks post RGX-121 administration, the median reduction in CSF HS from baseline was 29.5% in Cohort 1, 42.3% in Cohort 2, and 67.3% in Cohort 3. Cohorts 1 and 2 continued to demonstrate reductions in CSF HS at Week 24, with median reduction from baseline of 20.6% and 36.4%, respectively; one patient in Cohort 3 who had data at 24 weeks post-administration demonstrated a CSF HS reduction from baseline of 63.9%.

Similarly, dose-dependent reductions of CSF D2S6 were observed at last time point available following RGX-121 administration, with Cohort 3 patients approaching normal levels. The majority of patients in all three cohorts demonstrated reductions from baseline of D2S6 at the last time point available. The median reduction from baseline of D2S6 at Week 8 was 40.5% in Cohort 1, 50.9% in Cohort 2, and 80.5% in Cohort 3. Cohorts 1 and 2 continued to demonstrate reduction in D2S6 at Week 24, with median reduction from baseline of 33.0% and 61.8%, respectively; one patient in Cohort 3 who had data at 24 weeks post-administration demonstrated an 85.5% reduction from baseline of D2S6 at Week 24.

In addition, I2S protein concentration in the CSF, which was undetectable in all patients prior to dosing, was measurable in the majority of Cohort 2 and 3 patients after RGX-121 administration.

Neurodevelopmental Data

Improvements in neurodevelopmental function and Caregiver Reported Outcomes in Cohorts 1 and 2 demonstrated CNS activity up to two years after RGX-121 administration.

Eight patients had more than six months of follow up in neurodevelopmental assessments after RGX-121 administration, and data are reported for the BSID-III cognitive, expressive language and fine motor subtests. In the four patients who were above -2 standard deviations (SD) of the normative mean on the BSID-III cognitive subtest at baseline, three patients acquired skills and remained within two SD of the normative mean on the cognitive, expressive language, and fine motor subtests at the last time point available following RGX-121 administration; the fourth patient acquired expressive language skills. Of the four patients with baseline cognitive function below -2 SD from the normative mean, two patients demonstrated minimal skill acquisition in cognition, and one additional patient demonstrated minimal gains in expressive language following RGX-121 administration.

Patients also demonstrated improvements in Caregiver Reported Outcomes, including positive trends in toileting skills, reduction in maladaptive behaviors, and improved sleep breathing following RGX-121 administration.

Systemic Biomarker Data and Clinical Efficacy

Evidence of systemic enzyme expression and biomarker activity was observed in patients across all three cohorts. The majority of patients demonstrated increases in I2S protein concentration levels in plasma following administration of RGX-121.

Additionally, total urine GAG measures demonstrated evidence of a systemic effect of RGX-121, independent of ERT treatment. In all patients who continued to receive ERT, total urine GAG levels decreased at last time point available. One of two patients who was ERT-naïve demonstrated a notable decline in urine GAGs through the last time point available following RGX-121 administration. In the three patients who discontinued ERT approximately one year after administration of RGX-121, the total urine GAG levels following ERT withdrawal remained relatively consistent with total urine GAG levels prior to ERT withdrawal.

The study findings presented at the WORLDSymposium will be available under the Presentations & Publications page in the Media section of REGENXBIO’s website located at www.regenxbio.com.

About RGX-121

RGX-121 is designed to use the AAV9 vector to deliver the human iduronate-2-sulfatase gene (IDS) which encodes the iduronate-2-sulfatase (I2S) enzyme to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted I2S beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 has received orphan drug product, rare pediatric disease and Fast Track designations from the U.S. Food and Drug Administration.

About Mucopolysaccharidosis Type II (MPS II)

MPS II, or Hunter Syndrome, is a rare, X-linked recessive disease caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase (I2S) leading to an accumulation of glycosaminoglycans (GAGs), including heparan sulfate (HS) in tissues which ultimately results in cell, tissue, and organ dysfunction, including in the central nervous system (CNS). MPS II is estimated to occur in 1 in 100,000 to 170,000 births. In severe forms of the disease, early developmental milestones may be met, but developmental delay is readily apparent by 18 to 24 months. Specific treatment to address the neurological manifestations of MPS II remains a significant unmet medical need. Key biomarkers of I2S enzymatic activity in MPS II patients include its substrate heparan sulfate (HS), which has been shown to correlate with neurocognitive manifestations of the disorder.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Forward-Looking Statements

This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “assume,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would” or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO’s future operations and clinical trials. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO’s expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, the impact of the COVID-

19 pandemic or similar public health crises on REGENXBIO’s business, and other factors, many of which are beyond the control of REGENXBIO. Refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of REGENXBIO’s Annual Report on Form 10-K for the year ended December 31, 2020, and comparable “risk factors” sections of REGENXBIO’s Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (SEC) and are available on the SEC’s website at www.sec.gov. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Dana Cormack

Corporate Communications

dcormack@regenxbio.com

Investors:

Chris Brinzey

ICR Westwicke

339-970-2843

chris.brinzey@westwicke.com

EX-99.2 3 d276078dex992.htm EX-99.2 EX-99.2

EXHIBIT 99.2

 

LOGO

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposiumTM 2022

 

  •  

RGX-111, a potential one-time gene therapy for MPS I, is well-tolerated across two dose levels, with no drug-related serious adverse events

 

  •  

Biomarker and neurodevelopmental assessments indicate encouraging CNS profile in patients dosed with RGX-111

 

  •  

Evidence of systemic biomarker activity observed

 

  •  

Phase I/II trial data are consistent with positive results from an RGX-111 single-patient IND

 

  •  

Completed dosing of three patients in Cohort 2; Cohort 2 has been expanded to enroll up to 6 additional patients

ROCKVILLE, Md., February 9th, 2022 (PRNewswire) — REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient Investigational New Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).     

“This marks our first data presentation from the Phase I/II trial evaluating RGX-111 as a potential one-time gene therapy delivered directly to the central nervous system (CNS) for the treatment of severe MPS I. We are encouraged to see that RGX-111 has been well-tolerated with emerging evidence of CNS biomarker activity and improvements in neurodevelopmental function, which suggest biological activity in the CNS following one-time administration of RGX-111. We also saw emerging evidence of biomarker activity outside of the CNS,” said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO. “We plan to enroll additional patients in the Phase I/II trial and look forward to providing additional updates.”

“MPS I is a rare inherited disorder caused by a mutation in the gene that encodes human α-l-iduronidase (IDUA), an enzyme needed by cells to break down long chains of sugar molecules known as mucopolysaccharides. Current treatment options for MPS I have limitations and can be associated with significant morbidity and mortality,” said Ray Wang, M.D., Campbell Foundation Director of the Multidisciplinary Lysosomal Program, Division of Metabolic Disorders, CHOC Children’s Hospital / Department of Pediatrics, University of California, Irvine, CA. “Initial data indicate encouraging CNS and systemic biomarker activity following RGX-111 administration.”

RGX-111 is an investigational one-time gene therapy designed to deliver the gene that encodes the IDUA enzyme using the AAV9 vector. RGX-111 is administered directly to the CNS. The primary endpoint of the trial is to evaluate the safety of RGX-111. Secondary and exploratory endpoints include biomarkers of α-l-iduronidase (IDUA) enzyme activity in the cerebrospinal fluid (CSF), serum and urine, neurodevelopmental assessments, and caregiver reported outcomes. Patients were treated across two dose cohorts: 1.0x1010 genome copies per gram (GC/g) of brain mass (n=2) and 5.0x1010 GC/g of brain mass (n=3). In the single-patient IND for RGX-111, a severe MPS I patient was dosed with 1x1010 GC/g of brain mass.

REGENXBIO plans to immediately expand enrollment of patients in Cohort 2 of the Phase I/II trial based on support from MPS I treating-physicians and the Independent Data Monitoring Committee, to enroll up to six additional patients.

Data Summary and Safety Update

As of December 20, 2021, RGX-111 is reported to be well-tolerated in the five patients enrolled in the Phase I/II clinical trial with no drug-related serious adverse events (SAEs). Time of post-administration follow-up ranges from three weeks to 56 weeks. One patient in Cohort 1 has completed the 48-week immunosuppression regimen per the study protocol. Two patients were not receiving enzyme replacement therapy (ERT) at the time of enrollment, and they continue to not receive ERT.

RGX-111 continues to be well-tolerated in the single-patient IND with no drug-related SAEs as of December 20, 2021. Time of post-administration follow-up is 87 weeks. This patient has completed the 48-week immunosuppression regimen, per the study protocol, and continues to receive weekly ERT.

CSF Biomarker Data

Data from patients in the Phase I/II trial and the single-patient IND indicate positive IDUA biomarker activity in the CNS following one-time administration of RGX-111. Heparan sulfate (HS) is a glycosaminoglycan (GAG) that is a key biomarker of IDUA enzyme activity. In the Phase I/II trial, a decrease in HS in the CSF from baseline was observed through the last timepoint available in all four patients following administration of RGX-111. Measurable IDUA enzyme activity in the CSF was detected after RGX-111 administration in three of the four patients, all of whom had undetectable levels of IDUA activity at baseline.

The patient dosed with RGX-111 under the single-patient IND demonstrated a decrease from baseline in HS in the CSF at 59 weeks after dosing, the last timepoint available. IDUA enzyme activity in the CSF, which was at undetectable at baseline, was detected following RGX-111 administration.

Neurodevelopmental Data

Patients in the Phase I/II trial and the single-patient IND demonstrated encouraging continued neurodevelopment, as measured by age and using developmentally appropriate validated instruments for neurodevelopmental testing, including the Bayley Scales of Infant Development (BSID-III) for chronological or developmental ages 0-42 months, Wechsler Abbreviated Scale of Intelligence (WASI-II) for chronological and developmental age greater than six years, and the Vineland Adaptive Behavior Scale (VABS-III).

Three patients in the Phase I/II trial had neurodevelopmental assessments with at least one post-baseline assessment after administration of RGX-111. Early assessments from the two patients under the age of six years old demonstrated continued skill acquisition within two standard deviations of the normative mean at last assessment on the BSID-III cognition, expressive language and fine motor subtests. One patient in Cohort 1 who entered the trial at the age of 13 years old demonstrated neurodevelopmental improvements as measured by the WASI-II and six of the nine scales of the VABS-III at one year after RGX-111 administration.

The single-patient IND patient demonstrated continued skill acquisition within two standard deviations of the normative mean on the BSID-III cognition, expressive language and fine motor subtests, as well as higher age equivalent scores than available natural history data at last assessment, 20 months after administration of RGX-111.

Systemic Biomarker Data

Evidence of systemic biomarker activity was observed in patients in both cohorts of the Phase I/II trial and the single-patient IND. Patients who had elevated baseline levels of I0S6 in plasma, a key biomarker of IDUA enzyme activity in MPS I patients, demonstrated decreases in I0S6 levels following administration of RGX-111. In addition, patients dosed with RGX-111 maintained low levels of total urine GAGs at the last timepoint available, regardless of ERT treatment.

The study findings presented at the WORLDSymposium are available under the Presentations & Publications page in the Media section of the company’s website located at www.regenxbio.com.

About RGX-111

RGX-111 is designed to use the AAV9 vector to deliver the α-l-iduronidase (IDUA) gene to the central nervous system (CNS). Delivery of the IDUA gene within the cells in the central nervous system (CNS) could provide a permanent source of secreted IDUA beyond the blood-brain barrier, allowing for long-term cross-correction of cells throughout the CNS. By providing rapid IDUA delivery to the brain, RGX-111 could potentially help prevent the progression of cognitive deficits that otherwise occurs in MPS I patients. RGX-111 has received orphan drug product, rare pediatric disease and Fast Track designations from the U.S. Food and Drug Administration.

About Mucopolysaccharidosis Type I (MPS I)

MPS I is a rare autosomal recessive genetic disease caused by a deficiency in the lysosomal enzyme alpha-L-iduronidase (IDUA), leading to an accumulation of glycosaminoglycans (GAGs) including heparan sulfate (HS) in tissues which ultimately results in cell, tissue, and organ dysfunction, including in the central nervous system (CNS). This can include excessive accumulation of fluid in the brain, spinal cord compression, and cognitive impairment. MPS I is estimated to occur in 1 in 100,000 births. Current disease modifying therapies for MPS I include hematopoietic stem cell transplant (HSCT) and enzyme replacement therapy with a recombinant form of human IDUA administered intravenously. However, intravenous enzyme therapy does not treat the CNS manifestations of MPS I, and HSCT can be associated with clinically significant morbidity and mortality. Key biomarkers of IDUA enzymatic activity in MPS I patients include its substrate heparan sulfate (HS), which has been shown to correlate with neurocognitive manifestations of the disorder.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Forward-Looking Statements

This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “assume,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would” or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO’s future operations and clinical trials. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO’s expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, the impact of the COVID-19 pandemic or similar public health crises on REGENXBIO’s business, and other factors, many of which are beyond the control of REGENXBIO. Refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of REGENXBIO’s Annual Report on

Form 10-K for the year ended December 31, 2020, and comparable “risk factors” sections of REGENXBIO’s Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (SEC) and are available on the SEC’s website at www.sec.gov. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Dana Cormack

Corporate Communications

dcormack@regenxbio.com

Investors:

Chris Brinzey

ICR Westwicke

339-970-2843

chris.brinzey@westwicke.com

EX-101.SCH 4 rgnx-20220209.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 rgnx-20220209_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 rgnx-20220209_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g276078g0209042618238.jpg GRAPHIC begin 644 g276078g0209042618238.jpg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g276078g0209043039284.jpg GRAPHIC begin 644 g276078g0209043039284.jpg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htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Feb. 09, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001590877
Document Type 8-K
Document Period End Date Feb. 09, 2022
Entity Registrant Name REGENXBIO Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-37553
Entity Tax Identification Number 47-1851754
Entity Address, Address Line One 9804 Medical Center Drive
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code (240)
Local Phone Number 552-8181
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol RGNX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 d276078d8k_htm.xml IDEA: XBRL DOCUMENT 0001590877 2022-02-09 2022-02-09 false 0001590877 8-K 2022-02-09 REGENXBIO Inc. DE 001-37553 47-1851754 9804 Medical Center Drive Rockville MD 20850 (240) 552-8181 false false false false Common Stock, $0.0001 par value per share RGNX NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d276078d8k.htm d276078dex991.htm d276078dex992.htm rgnx-20220209.xsd rgnx-20220209_lab.xml rgnx-20220209_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d276078d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d276078d8k.htm" ] }, "labelLink": { "local": [ "rgnx-20220209_lab.xml" ] }, "presentationLink": { "local": [ "rgnx-20220209_pre.xml" ] }, "schema": { "local": [ "rgnx-20220209.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rgnx", "nsuri": "http://regenxbio.com/20220209", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d276078d8k.htm", "contextRef": "duration_2022-02-09_to_2022-02-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d276078d8k.htm", "contextRef": "duration_2022-02-09_to_2022-02-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenxbio.com//20220209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001193125-22-032205-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-032205-xbrl.zip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end